A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice

References

• Amin RP, Witz G. (2001). DNA-protein crosslink and DNA strand break formation in HL-60 cells treated with trans,trans-muconaldehyde, hydroquinone and their mixtures. Int J Toxicol 20:69–80.
   PubMed Web of Science ®Google Scholar
• Casado-Verrier B, Pérez-Santos S, Delgado-Mucientes C, Beato-Merino M. (2014). Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib. Br J Dermatol 171:1559–61.
   PubMed Web of Science ®Google Scholar
• Chen C, Krausz KW, Idle JR, Gonzalez FJ. (2008). Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 283:4543–59.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhu Y, Zhao Y, et al. (2016). Serum metabolomic profiling in a rat model reveals protective function of paeoniflorin against ANIT induced cholestasis. Phytother Res 30:654–62.
   PubMed Web of Science ®Google Scholar
• Cheng J, Ma XC, Gonzalez FJ. (2011). Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. Br J Pharmacol 163:461–8.
   PubMed Web of Science ®Google Scholar
• Choudhury Y, Toh YC, Xing J, et al. (2017). Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep 7:41238.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bortolini M. (2013). Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol 53:463–74.
   PubMed Web of Science ®Google Scholar
• Debbasch C, Brignole F, Pisella PJ, et al. (2001). Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 42:642–52.
   PubMed Web of Science ®Google Scholar
• Deng Y, Sychterz C, Suttle AB, et al. (2013). Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43:443–53.
   PubMed Web of Science ®Google Scholar
• DeVivo DC. (2002). Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 58:507.
   PubMed Web of Science ®Google Scholar
• Dinkic C, Eichbaum M, Schmidt M, et al. (2017). Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - results of the PACOVAR-trial. Gynecol Oncol 146:279–84.
   PubMed Web of Science ®Google Scholar
• Endo M, Nielsen TO. (2012). Pazopanib for metastatic soft-tissue sarcoma. Lancet 380:801.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Krausz KW, Li F, et al. (2012). Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol 167:1271–86.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Tosh DK, Tanaka N, et al. (2015). Metabolic mapping of A3 adenosine receptor agonist MRS5980. Biochem Pharmacol 97:215–23.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, Backman JT. (2012). Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165:2787–98.
   PubMed Web of Science ®Google Scholar
• Friling RS, Bensimon A, Tichauer Y, Daniel V. (1990). Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci USA 87:6258–62.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ando Y, Narabayashi M, et al. (2005). Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan. Drug Metab Dispos 33:1785–90.
   PubMed Web of Science ®Google Scholar
• Itoh K, Tong KI, Yamamoto M. (2004). Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36:1208–13.
   PubMed Web of Science ®Google Scholar
• Jain A, Canipari C, Haque F, et al. (2015). Liver toxicity associated with the use of pazopanib in renal cancer patients: UK teaching hospital experience. J Clin Oncol 51:S513.
   Web of Science ®Google Scholar
• Karch A, Koch A, Grunwald V. (2016). A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Trials 17:312.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Choueiri TK, Yee E, et al. (2012). Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol 30:e264–8.
   PubMed Web of Science ®Google Scholar
• Koinis F, Agelaki S, Karavassilis V, et al. (2017). Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer 117:8–14.
   PubMed Web of Science ®Google Scholar
• Li F, Jiang C, Krausz KW, et al. (2013). Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:2384.
   PubMed Web of Science ®Google Scholar
• Li F, Patterson AD, Hofer CC, et al. (2011). A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol 81:1043–53.
   PubMed Web of Science ®Google Scholar
• Li F, Patterson AD, Krausz KW, et al. (2012). Metabolomics reveals the metabolic map of procainamide in humans and mice. Biochem Pharmacol 83:1435–44.
   PubMed Web of Science ®Google Scholar
• Lim L, Mathias J, Lampron M, et al. (2013). Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy. Eur J Cancer 49:S660.
   Google Scholar
• Liu K, Yan J, Sachar M, et al. (2015a). A metabolomic perspective of griseofulvin-induced liver injury in mice. Biochem Pharmacol 98:493–501.
   PubMed Web of Science ®Google Scholar
• Liu X, Lu Y, Guan X, et al. (2015b). Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem Pharmacol 97:111–21.
   PubMed Web of Science ®Google Scholar
• Liu X, Lu YF, Guan X, et al. (2016). Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochem Pharmacol 109:70–82.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Shuster L, Mason RP. (1993). Reexamination of the microsomal transformation of N-hydroxynorcocaine to norcocaine nitroxide. Mol Pharmacol 43:645–8.
   PubMed Web of Science ®Google Scholar
• Lv QQ, Yang XN, Yan DM, et al. (2017). Metabolic profiling of dehydrodiisoeugenol using xenobiotic metabolomics. J Pharmaceut Biomed 145:725–33.
   PubMed Web of Science ®Google Scholar
• McBean GJ. (2017). Cysteine, glutathione, and thiol redox balance in astrocytes. Antioxidants 6:62.
   Web of Science ®Google Scholar
• Mingard C, Paech F, Bouitbir J, Krähenbühl S. (2018). Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol 38:418–31.
   PubMed Web of Science ®Google Scholar
• Minocha M, Khurana V, Qin B, et al. (2012). Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int J Pharm 436:127–34.
   PubMed Web of Science ®Google Scholar
• Pal SK, Hossain DMS, Zhang QF, et al. (2015). Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol 193:1114–21.
   PubMed Web of Science ®Google Scholar
• Patel PN, Kalariya PD, Sharma M, et al. (2015). Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction. J Mass Spectrom 50:918–28.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Williams D, Madden S, et al. (1995). Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984–90.
   PubMed Web of Science ®Google Scholar
• Rickmann M, Seidel C, Reuter C, et al. (2013). Treatment-associated liver-toxicity in patients with advanced metastatic renal cell carcinoma (mRCC) treated with Pazopanib. Onkologie 36:76–7.
   Google Scholar
• Rushmore TH, Morton MR, Pickett CB. (1991). The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266:11632–9.
   PubMed Web of Science ®Google Scholar
• Sedef AM, Köse F, Doğan Ö, et al. (2015). Targeted treatment with pazopanib in metastatic soft tissue sarcoma: nearly complete response in two cases. Mol Clin Oncol 3:400–2.
   PubMed Web of Science ®Google Scholar
• Shantakumar S, Nordstrom BL, Djousse L, et al. (2016). Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer Chemother Pharmacol 78:559–66.
   PubMed Web of Science ®Google Scholar
• Takimoto T, Kijima T, Otani Y, et al. (2013). Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin Lung Cancer 14:502–7.
   PubMed Web of Science ®Google Scholar
• Tan AR, Gibbon DG, Stein MN, et al. (2013). Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 71:1635–43.
   PubMed Web of Science ®Google Scholar
• Vlenterie M, Van Erp NP, Van der GWTA. (2015). Promising management of pazopanib-induced liver toxicity. Acta Oncol 54:1064–6.
   PubMed Web of Science ®Google Scholar
• Xie C, Gao X, Sun D, et al. (2018). Metabolic profiling of the novel hypoxia-inducible factor 2alpha inhibitor PT2385 in vivo and in vitro. Drug Metab Dispos 46:336–45.
   PubMed Web of Science ®Google Scholar
• Yang M, Ruan J, Gao H, et al. (2017a). First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 91:3912–25.
   Web of Science ®Google Scholar
• Yang XN, Lv QQ, Zhao Q, et al. (2017b). Metabolic profiling of myrislignan by UPLC-ESI-QTOFMS-based metabolomics. RSC Adv 7:40131–40.
   Web of Science ®Google Scholar
• Yapar K, Kart A, Karapehlivan M, et al. (2007). Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol 59:121–8.
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Gonzalez FJ. (2004). Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36:243–77.
   PubMed Web of Science ®Google Scholar
• Zakharyants AA, Burmistrova OA, Poloznikov AA. (2017). The use of human liver cell model and cytochrome P450 substrate-inhibitor panel for studies of dasatinib and warfarin interactions. Bull Exp Biol Med 162:515–9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Salminen A, Yang X, et al. (2017). Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria. Arch Toxicol 91:2921–38.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Yang R, Liu F, et al. (2017a). Metabolomics reveals that PPARa activation protects against lithocholic acid-induced liver injury. RSC Adv 7:49849–57.
   Web of Science ®Google Scholar
• Zhao Q, Yang R, Wang J, et al. (2017b). PPARalpha activation protects against cholestatic liver injury. Sci Rep 7:9967.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li XM, Liu HN, et al. (2018). Metabolic map of osthole and its effect on lipids. Xenobiotica 48:285–99.
   PubMed Web of Science ®Google Scholar